Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 1.00 |
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | CA9 | Q16790 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 1.00 |
| ▸ | CA6 | P23280 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 0.89 |
| ▸ | CA7 | P43166 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328336 | 0.94 | AKT1 (1.00) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9796270 | 0.87 | CA1 (1.00) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9796165 | 0.87 | CA1 (0.76) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9795893 | 0.87 | CA1 (1.00) | CA1CA2CA9CA12CA6 | |
| SCHEMBL11891697 | 0.87 | CA1 (0.76) | CA1CA2CA9CA12CA6 | |
| Benzolamide SCHEMBL3497931 | 0.86 | CA1 (1.00) | CA1CA2CA9CA12CA6 | |
| SCHEMBL12556025 | 0.83 | CA1 (0.71) | CA1CA2CA9CA12CA6 | |
| SCHEMBL4965134 | 0.83 | CA1 (1.00) | CA1CA2CA9CA12CA6 | |
| SCHEMBL14091067 | 0.81 | CA1 (0.68) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9796293 | 0.80 | CA1 (0.81) | CA1CA2CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428504-B1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | UNIV TEXAS (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2594265-B1 | Ca ix-specific inhibitors | INST VIROLOGY (SK) | 2015-10-28 | — | — | EP | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| US-8962663-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962663-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-24 | — | — | US | disclosed |
| US-20080145877-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080146618-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080145874-A1 | CA IX-Specific Inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-04-24 | — | — | US | disclosed |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-04-24 | — | — | US | disclosed |
| EP-1569633-A4 | CA IX-SPECIFIC INHIBITORS | INST VIROLOGY (SK) | 2008-03-05 | — | — | EP | disclosed |
| US-20060057068-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2006-03-16 | — | — | US | disclosed |
| EP-1569633-A2 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY (SK) | 2005-09-07 | — | — | EP | disclosed |
| US-20040146955-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2004-07-29 | — | — | US | disclosed |
| WO-2004048544-A2 | CA IX-SPECIFIC INHIBITORS | BAYER HEALTHCARE (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | CA1 4268/4885CA2 3465/4885CA9 4350/4885 |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | CA9, CA6, CA14 | CA1 4/4885CA2 5/4885CA9 1/4885 |
| US-20060057068-A1 | CA IX-specific inhibitors | CA9, CA2, CA6 | CA1 4/4885CA2 2/4885CA9 1/4885 |
| US-20080146618-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | CA2, CA9, CA1 | CA1 3/4885CA2 1/4885CA9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.